CClinicalTrials.gg
CompletedNCT06597929PA-strokeUpdated Jul 9, 2026

Moderate-vigorous Intermittent Physical Activity (M-VILPA) in Stroke

An interventional study of Moderate-vigorous physical activity in Physical Inactivity and Stroke, sponsored by Universitat Internacional de Catalunya. Completed at 1 site in Spain. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Universitat Internacional de Catalunya · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

Stroke is the leading cause of disability in Spain. Additionally, it is the second leading cause of death in women and the third in both sexes. Regular physical activity (PA) helps prevent and manage stroke. It also helps with hypertension, maintains a healthy body weight, and improves mental health, quality of life, and well-being. PA plays a prominent role in inpatient care after stroke. However, stroke survivors become more sedentary when discharged from the hospital. They have muscle weakness, reduced balance, and fatigue. Consequently, PA levels of community-dwelling post-stroke individuals remain lower than their age-matched counterparts. Continued PA can help this population maintain and improve physical function, and reduce long-term functional limitations, and mortality risk.

Read the detailed description

Previous studies that performed a comparative analysis of physical activity between individuals with and without stroke have consistently reported that stroke survivors tend to spend less time in moderate to vigorous physical activity The 2021 AHA guideline recommends smaller sessions of PA, with suggestions such as 10 minutes of moderate activity, 4 times a week, or 20 minutes of vigorous activity twice a week. This contrasts the weekly physical activity recommendations in 2011 (30 minutes of moderate to vigorous, 1 to 3 times) and 2014 (40 minutes of moderate to vigorous, 3 to 4 times). We hypothesise that older stroke survivors are physically active more frequently but for smaller durations than younger stroke survivors who are physically active for longer durations but less regularly. Understanding these subtle changes will not only help to tailor physical activity interventions based on specific recommendations but also help design future recommendations.

Moderate-to-vigorous PA could be an adequate approach for stroke survivors as it requires less time to achieve the same benefits as light PA. More concretely, a new concept called moderate-to-vigorous intermittent lifestyle physical activity (MV-ILPA) has recently emerged for adults who do not habitually exercise in their leisure time. MV-ILPA refers to brief and sporadic bouts of moderate-vigorous intensity PA performed as part of the activities of daily living, such as bursts of very fast walking, sitting and standing up from a chair, or stair climbing. MV-ILPA is associated with a substantially lower risk of all-cause cardiovascular disease and cancer mortality. However, there is no evidence to directly support the potential benefits of MV-ILPA in the elderly post-stroke patients.

02

Conditions studied

  • Physical Inactivity
  • Stroke

Keywords

  • Physical activity
  • Stroke
  • Moderate-vigorous physical activity
03

In context

Sedentary Behavior

333 studies on the registry are indexed under Sedentary Behavior; 156 are open to participants now.

This study's enrollment of 36 is below the median of 70 across 288 interventional studies indexed under Sedentary Behavior.

Browse Sedentary Behavior studies →

Lead sponsor

Universitat Internacional de Catalunya is the lead sponsor of 144 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • adults aged ≥50 in the late subacute phase post-stroke.
  • who live in the community
  • whose clinician confirmed a diagnosis of stroke (ischaemic/haemorrhagic)
  • discharged from hospital inpatient regimen
  • with independent mobility skills (Barthel Index ≥ 40 points).

Exclusion criteria

Exclusion Criteria:

  • other neurological diseases (e.g. Parkinson disease) or severe lower limb injuries.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Usual care plus the MV-ILPA and education program.

    The experimental group will receive usual care plus the MV-ILPA and education program. First, a physiotherapist will conduct a face-to-face session with the patients detailing the health benefits of moderate to vigorous PA and the negative effects of not including it in their daily lives. Patients will receive a booklet with all the key information. Secondly, participants will take the MV-ILPA program.

    Other: Moderate-vigorous physical activity

  • Active comparator
    Usual care

    Usual care: appointments with the treating neurologist, medication, conventional physiotherapy (two/three times a week, including stretching, strength, and balance training), occupational therapy, and speech therapy if required.

    Other: Moderate-vigorous physical activity

Interventions

  • OtherModerate-vigorous physical activity

    The experimental group will receive usual care plus the MV-ILPA and education program. First, a physiotherapist will conduct a face-to-face session with the patients detailing the health benefits of moderate to vigorous PA and the negative effects of not including it in their daily lives. Patients will receive a booklet with all the key information. Secondly, participants will take the MV-ILPA program. This program consists of completing 4 length-standardised moderate-to-vigorous intense bouts per day (3 minutes each) of activities of daily living (sit-to-stand, going up/down stairs, walking fast indoors, and walking up small slopes) every day for 12 weeks. Once per week for 12 weeks, a physiotherapist will go to the patient\'s home for a face-to-face session or videoconference. This physiotherapist will foster participants' independence and self-management. The PA intensity will be increased weekly by increasing the execution speed and including weights.

    Also known as: Moderate-vigorous exercise

06

What researchers measure

Primary outcomes

  1. The amount of moderate-vigorous intense physical activity (PA).

    All participants will be monitored with a 3-axial accelerometer (strapped on the waist) for 7 days to record their total daily movement counts and the minutes of moderate-to-vigorous-intensity PA.

    Time frame: From enrollment T0 (during 7 days) to the end of treatment at 12 weeks T1 (during 7 days) and at 12 weeks (follow-up) T2 (during 7 days)

Secondary outcomes

  1. Lower limb mean power

    The participants were instructed to rise from the chair, without armrests, as fast and powerful as possible, reaching a fully standing erect position without lifting their feet and sit back down as quickly as possible. Five attempts were given interspersed by 30-60 s. It is measured by Lineal Encoder Chronojump. Higher mean power means better outcome.

    Time frame: Day 0 T0, at 12-week T1 and 24-week follow-up T2

  2. Balance

    It will be assess by Berg Balance Scale, 0-56 points higher scores means better outcome

    Time frame: Day 0 T0, at 12-week T1 and 24-week follow-up

  3. Gait speed (comfortable and fast pace)

    4-metre walk test, less time mean better outcome

    Time frame: Day 0 T0, at 12-week T1 and 24-week follow-up T2

  4. Fatigue

    Fatigue Severity Scale, a 9-item questionnaire The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score = 9 and maximum score possible = 63. Higher score means worse outcome.

    Time frame: Day 0 T0, at 12-week T1 and 24-week follow-up T2

  5. Quality of life: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.

    It will be assess by EuroQol 5-dimension 5-level. The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). Each dimension of EQ-5D is described by 5 possible levels, scoring from 0 to 25 points. Higher score means worse outcome. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement.

    Time frame: Day 0 T0, at 12-week T1 and 24-week follow-up T2

  6. Degree of disability

    Modified-Rankin Scale, single-item global outcomes rating scale, from 0 to 5. Higher score means worse outcome.

    Time frame: Day 0 T0, at 12-week T1 and 24-week follow-up T2

  7. Stroke recurrence

    yes/no, date

    Time frame: Day 0 T0, at 12-week T1 and 24-week follow-up T2

  8. Death

    yes/no, date

    Time frame: Day 0 T0, at 12-week T1 and 24-week follow-up T2

  9. Falls

    number of falls

    Time frame: Day 0 T0, at 12-week T1 and 24-week follow-up T2

  10. Leg strength and endurance by 30 seconds sit to stand test

    The Test is administered using a folding chair without arms, with a seat height of 17 inches (43.2 cm). The chair, with rubber tips on the legs, is placed against a wall to prevent it from moving.The participant is seated in the middle of the chair, back straight; feet approximately a shoulder width apart and placed on the floor at an angle slightly back from the knees, with one foot slightly in front of the other to help maintain balance. Arms are crossed at the wrists and held against the chest.Demonstrate the task both slowly and quickly. Have the patient practice a repetition or two before completing the test. If a patient must use their arms to complete the test, they are scored 0. The participant is encouraged to complete as many full stands as possible within 30 seconds. The participant is instructed to fully sit between each stand. While monitoring the participant's performance to ensure proper form, the tester silently counts the completion of each correct stand.

    Time frame: Day 0 T0, at 12-week T1 and 24-week follow-up T2

  11. Basic Activities of daily living (Fundamental Self-Care)

    Barthel Index: Evaluates a person's functional status by measuring their ability to perform basic self-care tasks as: Bathing \& Hygiene: Washing body, brushing teeth, and grooming.Dressing: Selecting clothing and physically putting it on.Toileting: Getting to the toilet, using it, and cleaning oneself.Transferring: Moving in and out of a bed or chair.Continence: Managing bowel and bladder control.Feeding: Physically bringing food into the body (though preparing the food falls under IADLs).

    Time frame: Day 0 T0, at 12-week T1 and 24-week follow-up T2

07

Study locations

1 site
  • Sant Cugat del Valles
    Barcelona, Catalonia 08195, Spain
08

References and documents

Publications

  • Cabanas-Valdes R, Garcia-Rueda L, Salgueiro C, Perez-Bellmunt A, Rodriguez-Sanz J, Lopez-de-Celis C. Assessment of the 4-meter walk test test-retest reliability and concurrent validity and its correlation with the five sit-to-stand test in chronic ambulatory stroke survivors. Gait Posture. 2023 Mar;101:8-13. doi: 10.1016/j.gaitpost.2023.01.014. Epub 2023 Jan 20. PubMed 36696822 ↗
  • Kwakkel G, Stinear C, Essers B, Munoz-Novoa M, Branscheidt M, Cabanas-Valdes R, Lakicevic S, Lampropoulou S, Luft AR, Marque P, Moore SA, Solomon JM, Swinnen E, Turolla A, Alt Murphy M, Verheyden G. Motor rehabilitation after stroke: European Stroke Organisation (ESO) consensus-based definition and guiding framework. Eur Stroke J. 2023 Dec;8(4):880-894. doi: 10.1177/23969873231191304. Epub 2023 Aug 7. PubMed 37548025 ↗
  • Goncalves S, Le Bourvellec M, Duclos NC, Mandigout S. Recommended moderate to vigorous physical activity levels for people in the chronic phase of stroke can be achieved in outpatient physiotherapy: a multicentre observational study. Top Stroke Rehabil. 2025 Apr;32(3):219-228. doi: 10.1080/10749357.2024.2392447. Epub 2024 Aug 22. PubMed 39172127 ↗
  • Boyne P, Billinger SA, Reisman DS, Awosika OO, Buckley S, Burson J, Carl D, DeLange M, Doren S, Earnest M, Gerson M, Henry M, Horning A, Khoury JC, Kissela BM, Laughlin A, McCartney K, McQuaid T, Miller A, Moores A, Palmer JA, Sucharew H, Thompson ED, Wagner E, Ward J, Wasik EP, Whitaker AA, Wright H, Dunning K. Optimal Intensity and Duration of Walking Rehabilitation in Patients With Chronic Stroke: A Randomized Clinical Trial. JAMA Neurol. 2023 Apr 1;80(4):342-351. doi: 10.1001/jamaneurol.2023.0033. PubMed 36822187 ↗
  • Stamatakis E, Ahmadi MN, Friedenreich CM, Blodgett JM, Koster A, Holtermann A, Atkin A, Rangul V, Sherar LB, Teixeira-Pinto A, Ekelund U, Lee IM, Hamer M. Vigorous Intermittent Lifestyle Physical Activity and Cancer Incidence Among Nonexercising Adults: The UK Biobank Accelerometry Study. JAMA Oncol. 2023 Sep 1;9(9):1255-1259. doi: 10.1001/jamaoncol.2023.1830. PubMed 37498576 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06597929
Lead sponsor
Universitat Internacional de Catalunya
Collaborators
Corporacion Parc Tauli, Hospital de la Santa Creu de Vic, Hospital de Terrassa, Hospital de Granollers
Responsible party
Rosa Cabanas Valdés (PhD, Universitat Internacional de Catalunya) — Principal investigator
First posted
Sep 19, 2024
Start date
Apr 1, 2025
Primary completion
Jan 20, 2026
Completion
Apr 20, 2026
Last update
Jul 9, 2026

Study contacts

Rosa Cabanas-Valdés, PhD
principal investigator · Universitat Internacional de Catalunya

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion